CDR-404 is under clinical development by CDR-Life and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CDR-404’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CDR-404 overview

CDR-404 is under development for the treatment of solid tumors, melanoma, bladder cancer, esophageal cancer, head and neck squamous cell carcinoma and squamous non-small cell lung cancer. The drug candidate is a tri-specific antibody. It is a new biological entity being developed based on M-gager technology. It acts by targeting cells expressing melanoma associated antigen 4 (MAGE A4).

CDR-Life overview

CDR-Life is a biotechnology company that develops tumor-targeted immunotherapies. Its pipeline products include CDR202, CDR101, CDR404, CDR505, CDR106, CDR304 and others. The company’s products CDR101 is used in multiple myeloma; CDR3o4 is used in solid tumors, bladder cancer and squamous non-small cell lung cancer (NSCLC) and CDR202 is used against age-related macular degeneration. CDR-Life utilizes its proprietary technology LocATE (local activator and T cell engager) to develop novel antibody molecules or fragments that block the immunosuppressive signal in the synapse between tumor and T cells and will help advance the treatment for ophthalmological diseases and cancer. The company collaborates with University Hospital Zurich, ETH Zurich and other biopharmaceutical companies to conduct research to develop cancer immunotherapies. CDR-Life is headquartered in Horgen, Zurich, Switzerland.

For a complete picture of CDR-404’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.